药物之间的相互作用1329045个记录(本栏目收费,不能展示细节,电话13136136841)
药物之间的相互作用
Dobutamine
Cepeginterferon alfa-2B
The risk or severity of adverse effects can be increased when Dexamethasone is combined with Cepeginterferon alfa-2B.
Dobutamine
Gusperimus
The risk or severity of adverse effects can be increased when Dexamethasone is combined with Gusperimus.
Dobutamine
Mizoribine
The risk or severity of adverse effects can be increased when Dexamethasone is combined with Mizoribine.
Dobutamine
Guselkumab
The risk or severity of adverse effects can be increased when Dexamethasone is combined with Guselkumab.
Dobutamine
Sirukumab
The risk or severity of adverse effects can be increased when Dexamethasone is combined with Sirukumab.
Dobutamine
Brodalumab
The risk or severity of adverse effects can be increased when Dexamethasone is combined with Brodalumab.
Dobutamine
Sarilumab
The risk or severity of adverse effects can be increased when Dexamethasone is combined with Sarilumab.
Dobutamine
Peficitinib
The risk or severity of adverse effects can be increased when Dexamethasone is combined with Peficitinib.
Dobutamine
Voclosporin
The risk or severity of adverse effects can be increased when Dexamethasone is combined with Voclosporin.
Dobutamine
Pirarubicin
The risk or severity of adverse effects can be increased when Dexamethasone is combined with Pirarubicin.
Dobutamine
Ravulizumab
The risk or severity of adverse effects can be increased when Dexamethasone is combined with Ravulizumab.
Dobutamine
Ixekizumab
The risk or severity of adverse effects can be increased when Dexamethasone is combined with Ixekizumab.
Dobutamine
Antilymphocyte immunoglobulin (horse)
The risk or severity of adverse effects can be increased when Dexamethasone is combined with Antilymphocyte immunoglobulin (horse).
Dobutamine
Peginterferon beta-1a
The risk or severity of adverse effects can be increased when Dexamethasone is combined with Peginterferon beta-1a.
Dobutamine
Vilanterol
The risk or severity of adverse effects can be increased when Dexamethasone is combined with Vilanterol.
Dobutamine
Dinutuximab
The risk or severity of adverse effects can be increased when Dexamethasone is combined with Dinutuximab.
Dobutamine
Blinatumomab
The risk or severity of adverse effects can be increased when Dexamethasone is combined with Blinatumomab.
Dobutamine
Vedolizumab
The risk or severity of adverse effects can be increased when Dexamethasone is combined with Vedolizumab.
Dobutamine
Obinutuzumab
The risk or severity of adverse effects can be increased when Dexamethasone is combined with Obinutuzumab.
Dobutamine
Dimethyl fumarate
The risk or severity of adverse effects can be increased when Dexamethasone is combined with Dimethyl fumarate.